Why Vitamin C is the Most Underrated Nutrient for Heart Health

Summary

The video argues that vitamin C may be an underappreciated contributor to cardiovascular health. The presenter describes several possible mechanisms and proposes a vitamin C–lysine supplement protocol, while acknowledging that evidence—particularly for lowering Lp(a) in humans—is limited and mixed.

Main ideas

• Lp(a) and vitamin C: Lp(a) is described as an LDL-like particle with an additional protein, apolipoprotein(a), that may promote clotting and atherosclerosis. The presenter reviews Linus Pauling and Dr. Rath’s hypothesis that Lp(a) may have partly evolved as a substitute for vitamin C’s role in wound healing in species, including humans, that cannot make their own vitamin C. He presents animal and cross-species observations in support of the idea, but it remains a hypothesis rather than an established explanation.
• Evidence in people is mixed: Some observational studies linked higher vitamin C intake or blood levels with lower cardiovascular risk. However, observational findings cannot establish cause and effect, and other studies have not found benefits.
• Some clinical trials showed favorable cardiovascular measures: The presenter cites trials reporting improved flow-mediated dilation, slower vessel re-narrowing after angioplasty, and slower progression of carotid atherosclerosis. These findings concern particular measures and study populations; they do not, on their own, prove that supplementation prevents heart attacks or lowers mortality.
• Three proposed ways vitamin C may support heart health:
  1. Potentially make Lp(a) less harmful: Vitamin C may support collagen formation, which the presenter suggests could reduce the “handholds” Lp(a) uses to bind to clots.
  2. Reduce oxidative damage: As an antioxidant, vitamin C may lower oxidized LDL and help protect blood-vessel cells from its effects.
  3. Support nitric oxide and vessel function: The presenter says vitamin C can stabilize BH4, a cofactor for nitric oxide-producing enzymes, potentially supporting blood-vessel relaxation and function.
• People may respond differently: The presenter suggests benefits could vary with a person’s risk factors—for example, Lp(a), oxidative stress, or impaired blood-vessel function. This is offered as a possible explanation for inconsistent results across studies.
• RDA versus the presenter’s suggested range: The video notes that the recommended daily allowance for vitamin C is 90 mg for men and 75 mg for women, and argues that an RDA is not necessarily an optimal target. The presenter suggests a broad range of 250 mg to 2,000 mg daily, while emphasizing that the range is imprecise. He also shows a table ranking common fruits and vegetables by vitamin C content and vitamin C relative to net carbohydrates.

Protocol and monitoring discussed

The presenter’s proposed non-prescription protocol is:

• Vitamin C: 1,000 mg per day, divided into two 500 mg doses.
• Lysine: 2,000 mg per day.

The proposed rationale is that vitamin C may support collagen and blood-vessel function, while lysine may act as a decoy at Lp(a)’s lysine-binding sites, potentially making Lp(a) less able to bind to clots. The intended effect is mainly to reduce Lp(a)’s “stickiness,” not necessarily its blood level. The presenter says he would not expect a major change in Lp(a) levels based on the available human evidence.

For someone tracking the proposed protocol, the presenter suggests considering:

• Lp(a) measurements before and after supplementation.
• Vitamin C levels, potentially after 4–8 weeks.
• Oxidized LDL and oxidized phospholipids as markers related to oxidative stress.
• IL-6, an inflammatory marker that the presenter says may be connected with Lp(a) and atherosclerosis.

The video presents this approach as a rationale-based suggestion, not a prescription. Its claims about supplementation and cardiovascular outcomes should be understood in light of the mixed human evidence described in the video.

Speakers and sources featured

• Speaker: Nick Norwitz, the video’s presenter. No guest interview speakers appear in the subtitles.
• Researchers and sources discussed: Linus Pauling and Dr. Rath; the Nurses’ Health Study; the EPIC study; and unnamed randomized trials and animal studies involving guinea pigs and mice. The presenter also refers generally to research on Lp(a), clot breakdown, oxidized LDL, BH4, nitric oxide, and IL-6.